Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis

ClinicalTrials.gov ID: NCT02311881

Public ClinicalTrials.gov record NCT02311881. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 20, 2026, 6:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Efficacy and Safety Study of Sustained-release Paracetamol in Subjects With Osteoarthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to determine whether paracetamol 1000 mg sustained-release (SR) tablets administered orally, twice daily are effective and safe in the treatment of patients with osteoarthritis of the knee or hip.

Study identification

NCT ID
NCT02311881
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
960 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2014
Primary completion
Jan 31, 2016
Completion
Jan 31, 2016
Last update posted
Apr 6, 2017

2015 – 2016

United States locations

U.S. sites
56
U.S. states
20
U.S. cities
49
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35242
GSK Investigational Site Huntsville Alabama 35801
GSK Investigational Site Chandler Arizona 85224
GSK Investigational Site Tucson Arizona 85712
GSK Investigational Site Tucson Arizona 85745
GSK Investigational Site Anaheim California 92801
GSK Investigational Site Carmichael California 95608
GSK Investigational Site Fresno California 93702
GSK Investigational Site North Hollywood California 91606-1559
GSK Investigational Site San Diego California 92103
GSK Investigational Site Brandon Florida 33511
GSK Investigational Site Clearwater Florida 33756
GSK Investigational Site Edgewater Florida 32132
GSK Investigational Site Hialeah Florida 33012
GSK Investigational Site Hialeah Florida 33016
GSK Investigational Site Homestead Florida 33030
GSK Investigational Site Jupiter Florida 33458
GSK Investigational Site Miami Florida 33155
GSK Investigational Site Miami Florida 33173
GSK Investigational Site Miami Florida 33185
GSK Investigational Site Oldsmar Florida 34677
GSK Investigational Site Orlando Florida 32806
GSK Investigational Site Oviedo Florida 32765
GSK Investigational Site Port Orange Florida 32127
GSK Investigational Site South Miami Florida 33143
GSK Investigational Site West Palm Beach Florida 33409
GSK Investigational Site Savannah Georgia 31406
GSK Investigational Site Chicago Illinois 60640
GSK Investigational Site Evanston Illinois 60201
GSK Investigational Site Prairie Village Kansas 66206
GSK Investigational Site Wichita Kansas 67203
GSK Investigational Site Crestview Hills Kentucky 41017
GSK Investigational Site New Orleans Louisiana 70115
GSK Investigational Site Watertown Massachusetts 02472
GSK Investigational Site St Louis Missouri 63139
GSK Investigational Site Bellevue Nebraska 68005
GSK Investigational Site Omaha Nebraska 68134
GSK Investigational Site Las Vegas Nevada 89119
GSK Investigational Site Brooklyn New York 11230
GSK Investigational Site Buffalo New York 14223
GSK Investigational Site Hartsdale New York
GSK Investigational Site Hickory North Carolina 28601
GSK Investigational Site Cincinnati Ohio 45227
GSK Investigational Site Cincinnati Ohio 45242
GSK Investigational Site Cincinnati Ohio 45255
GSK Investigational Site Dayton Ohio 45424
GSK Investigational Site Toledo Ohio 43623
GSK Investigational Site Oklahoma City Oklahoma 73119
GSK Investigational Site Altoona Pennsylvania 16602
GSK Investigational Site Duncansville Pennsylvania 16635
GSK Investigational Site Smithfield Pennsylvania 15478
GSK Investigational Site Mt. Pleasant South Carolina 29464
GSK Investigational Site Dallas Texas 75230
GSK Investigational Site Plano Texas 75075
GSK Investigational Site San Antonio Texas 78209
GSK Investigational Site San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02311881, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 6, 2017 · Synced Sep 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02311881 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →